Inhibition of human immunodeficiency virus type 1 wild-type and mutant reverse transcriptases by the phenyl ethyl thiazolyl thiourea derivatives trovirdine and MSC-127

Antiviral Research

Volumn 28, Issue 4, 1995, Pages 331-342

  Zhang, Hong ^a,b   Vrang, Lotta ^a   Bäckbro, Kristina ^c   Lind, Peter ^a   Sahlberg, Christer ^a   Unge, Torsten ^c   Öberg, Bo ^a,b  

^a MEDIVIR AB   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

Enzyme kinetics; Human immunodeficiency virus (HIV) reverse transcriptase; Inhibitor; Mutant; Trovirdine

Indexed keywords

1 (5 BROMO 2 PYRIDYL) 3 (2 PYRIDYL)THIOUREA; 3 [(4,7 DICHLORO 2 BENZOXAZOLYLMETHYL)AMINO] 5 ETHYL 6 METHYL 2(1H) PYRIDONE; 9 CHLORO TIBO; ANTIVIRUS AGENT; MSC 127; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; THIOUREA DERIVATIVE; TROVIRDINE; UNCLASSIFIED DRUG;

ARTICLE; ENZYME INHIBITION; HUMAN IMMUNODEFICIENCY VIRUS 1; MUTANT; PRIORITY JOURNAL;

ANTIVIRAL AGENTS; BASE SEQUENCE; ENZYME ACTIVATION; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; KINETICS; MOLECULAR SEQUENCE DATA; MUTATION; PYRIDINES; REVERSE TRANSCRIPTASE INHIBITORS; RNA-DIRECTED DNA POLYMERASE; THIOUREA;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0028885715     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/0166-3542(95)00056-9     Document Type: Article

References (36)

1. A new class of potent nonnucleoside inhibitor of human immunodefiency virus type 1 reverse transcriptase
2. Action of pancreatic DNase requirement of DNA as template-primer for DNA polymerase a
3. Analysis of nonnucleoside drug-resistant variants of human immunodeficiency virus type 1 reverse transcriptase
4. Comprehensive mutant enzyme and viral variant assessment of human immunodeficiency virus type 1 reverse transcriptase resistance to nonnucleoside inhibitors
5. Susceptibilities of human immunodeficiency virus type 1 enzyme and viral variants expressing multiple resistance-engendering amino acid substitutions to reverse transcriptase inhibitors
6. Identification of the human immunodeficiency virus reverse transcriptase residues that contribute to the activity of diverse nonnucleoside inhibitors
7. Inhibition of HIV-1 reverse transcriptase by pyridinone derivatives
8. An antiviral target on reverse transcriptase of human immunodeficiency virus type 1 revealed by tetrahydroimidazo-[451-jk]benzadiazepin-2(1H)-one and -thione derivatives
9. Common features in the interaction of tetrahydroimidazo[4,5,1-jk] [1,4] benzodiazepin-2(1 H)-one and -thione and 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives with the human immunodeficiency virus type 1 reverse transcriptase
10. Basic approaches to anti-retroviral treatment
11. HIV inhibitors targeted at the reverse transcriptase
12. HIV-1 specific RT inhibitors: highly selective inhibitors of human immunodeficiency virus type 1 that are specifically targeted at the viral reverse transcriptase
13. Kinetic interaction of human immunodeficiency virus type 1 reverse transcriptase with the antiviral tetrahydromidazo[4,5,1-jk]-[1,4]-benzodiazepine-2-(1H)-thione compound, 82150
14. Factors contributing to the inhibition of HIV reverse transcriptase by chain-terminating nucleosides in vitro and vivo
15. Pyridinone derivatives: specific human immunodeficiency virus type 1 reverse transcriptase inhibitors with antiviral activity
16. A nonnucleoside reverse transcriptase inhibitor active on human immunodeficiency virus type 1 isolates resistant to related inhibitors
17. Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 1. Tricyclic pyridobenzo- and dipyridodiazepinones
18. Specific inhibition of the reverse transcriptase of human immunodeficiency virus type 1 and the chimeric enzymes of human immunodeficiency virus type 1 and type 2 by nonnucleoside inhibitors
19. Steady state kinetics and inhibition of HIV-1 reverse transcriptase by a non-nucleoside dipyridiazepinone BI-RG-587, using a heteropolymeric template
20. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor
21. Studies on the mechanism of human immunodeficiency virus reverse transcriptase
22. Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor
23. In vitro selection and molecular characterization of human immunodeficiency virus-1 resistant to non-nucleoside inhibitors of reverse transcriptase
24. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives
25. Human immunodeficiency virus reverse transcriptase
26. Human immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissus culture
27. Functional analysis of HIV-1 reverse transcriptase amino acids involved in resistance to multiple non-nucleoside inhibitors
28. Use of T7 DNA polymerase to direct expression of cloned genes
29. Antiviral therapy in human immunodeficiency virus infections, Current status (Part I)
30. Antiviral therapy in human immunodeficiency virus infections, Current status (Part II)
31. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors
32. HIV-1 reverse transcriptase inhibition by a dipyridodiazepinone derivative, BI-RG-587
33. Expression, purification and crystallisation of the HIV-1 reverse transcriptase (RT)
34. A TIBO derivative, R82913, is a potent inhibitor of HIV-1 reverse transcriptase with heteropolymer template
35. 6.1. Characterization of HIV reverse transcriptase with Tyr181 → Cys and Leu100 → Ile mutations
36. Enzymatic properties and sensitivity to inhibitors of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase with Glu138 → Arg and Tyr188 → His mutations